Sanofi SA

SNY

Company Profile

  • Business description

    Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

  • Contact

    46, Avenue de la Great Army
    Paris75017
    FRA

    T: +33 153774000

    E: [email protected]

    https://www.sanofi.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2025

    Employees

    82,878

Stocks News & Analysis

stocks

10 best US blue-chip stocks to buy for the long term

The stocks of these high-quality companies with large market capitalisations look undervalued today.
personal-finance

Can you achieve global diversification with multinational companies?

A Morningstar report explores if the benefits of global investing can be achieved by investing in global companies trading on local exchanges.
stocks

Magnificent Seven vs. the ‘Granolas’: How does Europe’s version stack up?

‘Granolas’ stocks are profitable, diversified, cheap—and posting big returns.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,631.5042.700.50%
CAC 407,826.791.34-0.02%
DAX 4024,226.49198.840.83%
Dow JONES (US)42,343.65740.581.78%
FTSE 1008,778.0560.080.69%
HKSE23,381.9999.660.43%
NASDAQ19,199.16461.962.47%
Nikkei 22537,724.11192.580.51%
NZX 50 Index12,582.330.000.00%
S&P 5005,921.54118.722.05%
S&P/ASX 2008,407.6046.600.56%
SSE Composite Index3,340.696.15-0.18%

Market Movers